<DOC>
	<DOCNO>NCT02628743</DOCNO>
	<brief_summary>The purpose study evaluate safety olesoxime participant spinal muscular atrophy , focus nature , frequency , severity adverse event , well effect laboratory value , vital sign ECG parameter .</brief_summary>
	<brief_title>A Study Evaluate Long Term Safety , Tolerability , Effectiveness Olesoxime Patients With Spinal Muscular Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>Participation previous study ( TRO19622CLEQ11151 TRO19622CLEQ12751 ) Able comply study protocol , investigator 's judgment , include ability take study treatment perform study visit For woman childbearing potential : agreement use acceptable birth control method treatment period least 28 day last dose olesoxime Female participant pregnant lactating , intend become pregnant study Participants , opinion investigator , suitable participate openlabel study Participants develop study drug hypersensitivity olesoxime one formulation excipients , include sesame oil Concomitant previous participation investigational drug device study within 90 day prior screen Concomitant previous participation SMN2targeting antisense oligonucleotide study within 6 month prior screen History human immunodeficiency virus infection , history Hepatitis B infection within past year , history Hepatitis C infection adequately treat History illicit drug alcohol abuse within 12 month prior screen , investigator 's judgment Any serious medical condition abnormality clinical laboratory test , investigator 's judgment , preclude participant 's safe participation completion study History presence abnormal ECG clinically significant investigator 's opinion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>